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Conclusions 
• Individuals with a history of psychotic disorders are able to achieve smoking 
cessation when provided evidence-based treatment.  
• However, tailored approaches specific to the needs of individuals with 
psychotic disorders may be warranted to enhance cessation outcomes. 
• Future studies may be required to further understand how to tailor treatment 
outcomes and modify existing treatment approaches to optimize outcomes 
among individuals with a history of psychotic and other psychiatric disorders. 
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• There is higher smoking-prevalence and smoking-attributable mortality 
among individuals with a psychotic disorders (e.g., Schizophrenia, 
Schizoaffetive disorder) relative to those with other psychiatric disorders.  
• Although smokers with psychotic disorders are willing to engage in 
smoking cessation, there are limited resources available to this population 
within mental health services. 
•A growing number of studies have examined the efficacy of different 
behavioural and pharmacological tobacco treatment approaches among 
individuals with psychotic disorders.  
• However, few studies in Canada have examined the effective of such 
approaches when applied within real-world mental health and addictions  
services.  
•The objectives of our study are to: 1) describe the characteristics of 
smokers with a history of psychotic disorders as compared to other 
disorders (i.e., none vs. depression/anxiety) and 2) examine smoking 
cessation/reduction outcomes by history of psychiatric disorders.  
Background 
The TDC provides an individualized and tailored tobacco treatment 
programme for a duration of up to 26 weeks (i.e., 6-months). 
Pharamcotherapy: NRT, varenicline, or bupropion is provided at no-cost 
to participants and is tailored to their particular need following a ‘titration 
to effect’ model. Hence it is not uncommon for participants to be provided 
with combination smoking cessation products.  
Behavioural Therapy: Behavioural therapy consists of an initial mandatory 
weekly 8-session (1.5 hrs/session) structured, manualised group 
programme, followed by an optional up to 18 weeks of group therapy 
following a ‘support group’ style.  
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Methods 
• This study is based on a retrospective review of the charts of 982 
participants of the Vancouver Coastal Health Mental Health and Addictions 
Services Tobacco Dependence Clinic (TDC) (between Sept 2007 and 
December 2012).  
•Data on demographics, smoking and cessation attempt history, nicotine 
dependence scores, importance and confidence in quitting smoking, expired 
carbon monoxide (expCO) level, history of polysubstance use, and number of 
visits to the program (see table 1). 
• The main outcomes of interest were: a) self-reported 7-day point-prevalence 
of smoking abstinence verified by expCO level, and b) smoking reduction 
(defined by a 50% or more reduction in average number of cigarettes smoked 
per day compared to baseline for those who did not achieve abstinence). 
Table 2. Multivariate Predictorsa of End of Treatment Smoking Cessation for 
Program Completer (n=543)b by History of Psychiatric disorder  
Results 
• As compared to those with no psychiatric disorder, individuals with psychotic disorders 
were more likely to have initiated smoking at an older age, report lower importance and 
confidence in quitting, smoke a greater number of cigarettes per day, and be more 
nicotine dependent.  
• 35.7% of those with a psychotic disorder achieved smoking cessation (as compared to 
no psychiatric disorder = 45.6% vs. depressive/anxiety disorder = 39.6%,  p =.350). 
Among programme completers (n = 543), there was a significant linear trend towards 
greater cessation with a greater number of visits to the programme in the total sample, 
among those without a psychiatric disorder, and among those with depressive/anxiety 
disorders  (see Figure 1). However, this trend was non-significant (p<.061) among 
those with a psychotic disorder. 
• 59.3% of individuals with a psychotic disorder achieved smoking reduction (as 
compared to no psychiatric disorder = 74.1% vs. depressive/anxiety = 67.3%, p =.370).  
•In stratified multivariate analysis (table 2), predictors of smoking cessation were: a) 
having a greater number of visits to the programme among those without a psychiatric 
disorder, b) having a lower baseline expCO level among those with a psychotic 
disorder, and c) a greater length of abstinence at the last quit attempt and a greater 
number of visits to the programme among those with depressive/anxiety disorders.  
  Total 
(N = 982) 
Nonea 
(n = 256) 
Psychotica 
(n = 109) 
Depression/Anxietya 
(n = 617) 
  n % n % n % n % 
Gender***(n = 977)                 
Female  398 40.7 73 28.6 42 38.9 283 46.1 
Male 579 59.3 182 71.4 66 61.1 331 53.9 
Has used any evidence-based cessation 
methods (i.e., NRT, Oral meds, and/or 
behavioural therapy) in the past  
                
No  414 42.2 113 44.1 48 44.0 253 41.0 
Yes 568 57.8 143 55.9 61 56.0 364 59.0 
History of Polysubstance Use                 
None 130 13.2 36 14.1 20 18.3 74 12.0 
One 329 33.5 84 32.8 40 36.7 205 33.2 
Two 259 26.4 61 23.8 26 23.9 172 27.9 
Three or more 264 26.9 75 29.3 23 21.1 166 26.9 
                  
  Mean SD Mean SD Mean SD Mean SD 
Age (years)  (n = 981) 47.3 11.5 48.1 13.0 49.1 10.2 46.6 11.0 
Age at smoking initiation*(n = 974)  15.2 5.7 15.0 5.4 17.1 8.0 14.9 5.4 
Quit length at last attempt  (n = 981) 2.7 1.6 2.7 1.6 2.7 1.8 2.7 1.5 
Importance* (n = 944). 9.0 1.3 9.2 1.3 9.0 1.4 9.0 1.3 
Confidence** (n = 933) 7.3 2.3 7.7 2.2 6.8 2.5 7.3 2.4 
CPD*  (n = 980) 20.0 10.8 19.3 11.6 23.4 15.1 19.7 9.4 
FTND* (n = 959) 5.8 2.2 5.4 2.4 6.0 2.4 5.9 2.1 
Baseline CO (n = 936) 20.0 13.5 20.5 16.3 20.5 13.1 19.7 12.3 
 Total number of visits to the programme  9.0  8.1  8.4 7.8   9.4 8.9  9.2  8.1  
Table 1. Sample Characteristics by Psychiatric Disorder History (N = 982) 
*p < .05, **p < .01, ****p < .001  
 
Note: Group differences are calculated using chi-square analyses for categorical and ordered categorical values, and using Analysis of Variance (ANOVA) tests For all ANOVA tests, Levene’s 
test for equality of variance was applied and differences between groups were calculated post hoc using Bonferroni and LSD tests. In addition, Kruskal-Wallis Tests were employed for variables 
with unequal variances all p-values are based on the Kruskal-Wallis tests. 
a. The None group includes 256 individuals with a substance use disorder or other addictive disorder without a mental illness. Psychotic group includes individuals with a history of only a 
psychotic disorder (i.e., schizophrenia, schizoaffective disorder, psychosis not otherwise specified, n=70) and those with a history or psychotic disorder and co-morbid depressive or anxiety 
disorder (n = 71) 
The Depression/Anxiety group include individuals with a history of primarily a depressive disorder (i.e., major depressive disorder, bipolar disorder, n = 231), those with primarily an anxiety 
disorder (posttraumatic stress disorder, generalized anxiety disorder, agoraphobia, social anxiety disorder, n = 62), and individuals with a history of comorbid depressive and anxiety disorder (n 
= 324). 
  None 
 (n = 136) d 
Psychoticc 
 (n = 54) d 
Depressive/Anxietyc 
 (n = 339)d 
  Odds Ratio 95%CI Odds Ratio 95%CI Odds Ratio 95%CI 
Gender              
Female .51 .24-1.10 - - - - 
Male (referent)             
              
Age at smoking initiation  -  - -  -  1.02 .98-1.07 
              
Quit length at last attempt    - -  -  -  1.25** 1.07-1.45 
              
Confidence - - 1.19 .91-1.56  -  - 
              
FTND at baseline - - - - .88 .78-.1.00 
              
CO level at baseline - - .92* .87-.99 .99 .97-1.01 
              
Total number of visits to the TDC 1.08** 1.02-1.14 1.08 .99-1.18 1.06** 1.03-1.10 
*p <.05, **= p<.01, *** = p <.001 
 
a Only variables that were significantly predictive of smoking cessation at p< 1.0 in the univariate logistic regression in each stratified analysis were included in the multivariate analysis.   
b. The program involves 8 weeks of a closed group therapy session followed by a further up to 18 weeks of optional support group. A program completer had to complete the 8 week closed group with 
no more than two weeks of excused absences to still have meaningful participation in the program.  
c. The Psychotic group includes individuals with a history of only a psychotic disorder (i.e., schizophrenia, schizoaffective disorder, psychosis not otherwise specified, n=70) and those with a history or 
psychotic disorder and co-morbid depressive or anxiety disorder (n = 71). The Depression/Anxiety group include individuals with a history of primarily a depressive disorder (i.e., major depressive 
disorder, bipolar disorder, n = 231), those with primarily an anxiety disorder (posttraumatic stress disorder, generalized anxiety disorder, agoraphobia, social anxiety disorder, n = 62), and individuals 
with a history of comorbid depressive and anxiety disorder (n = 324). 
d None, Hosmer-Lemeshow goodness-of-fit: n = 136,  χ2= 8.37 (DF=7), p=.301 
d Psychotic Disorder; Hosmer-Lemeshow goodness-of-fit: n = 54,  χ2= 4.02 (DF=8),  p=.856; 
d Depressive/Anxiety, Hosmer-Lemeshow goodness-of-fit: n = 339,  χ2= 8.18 (DF=8),  p=.416 
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Figure 1. Smoking cessation outcomes by length of time in programme stratified by psychiatric 
illness among programme completers (n = 543) 
** 
*** 
**p<.01, ***p<.0001 
